Inhibrx Biosciences Inc expected to post a loss of $2.76 a share - Earnings Preview

Inhibrx Biosciences

09/08/2025 24:39

Inhibrx Biosciences Inc INBX.OQ INBX.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Inhibrx Biosciences Inc is for a loss of $2.76 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Inhibrx Biosciences Inc is $12.00, about 75.5% below its last closing price of $21.06

This summary was machine generated August 8 at 23:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)